HOTAIR is a potential target for the treatment of cisplatin‑resistant ovarian cancer

  • Authors:
    • Yu Wang
    • Hongli Wang
    • Tiefang Song
    • Yiting Zou
    • Jing Jiang
    • Lei Fang
    • Peiling Li
  • View Affiliations

  • Published online on: March 27, 2015     https://doi.org/10.3892/mmr.2015.3562
  • Pages: 2211-2216
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Previous studies have demonstrated that the presence of Hox transcript antisense intergenic RNA (HOTAIR) is correlated with poor survival in several types of cancer, including breast cancer, and promotes tumor metastasis. Currently, little is known regarding the correlation between HOTAIR and chemoresistance in cancer. The current study aimed to investigate the role of HOTAIR in epithelial ovarian cancer, and the correlation between HOTAIR and cisplatin resistance. Reverse transcription-quantitative polymerase chain reaction was conducted to detect HOTAIR expression in the ovarian specimens and ovarian carcinoma cell lines. The results indicated that the expression level of HOTAIR was higher in epithelial ovarian cancer tissues than the level in the benign ovarian tissues. The expression level was also higher in late‑stage malignant ovarian tumors compared with the level in early‑stage tumors. Levels of HOTAIR were also higher in the SKOV‑3CDDP/R cisplatin‑resistant ovarian carcinoma cell line than in the SKOV‑3 cisplatin‑sensitive cell line. The knockdown of HOTAIR using siRNAs with transfection reagent suppressed cell proliferation, reduced the invasion ability of the cells and notably, it restored cisplatin‑sensitivity of the cisplatin‑resistant cells specifically by enhancing cisplatin‑induced cytotoxicity and apoptosis in SKOV‑3CDDP/R cells. In conclusion, HOTAIR may be used in the development of novel treatments for ovarian cancer, particularly those that are resistant to conventional therapies.
View Figures
View References

Related Articles

Journal Cover

August-2015
Volume 12 Issue 2

Print ISSN: 1791-2997
Online ISSN:1791-3004

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Wang Y, Wang H, Song T, Zou Y, Jiang J, Fang L and Li P: HOTAIR is a potential target for the treatment of cisplatin‑resistant ovarian cancer. Mol Med Rep 12: 2211-2216, 2015
APA
Wang, Y., Wang, H., Song, T., Zou, Y., Jiang, J., Fang, L., & Li, P. (2015). HOTAIR is a potential target for the treatment of cisplatin‑resistant ovarian cancer. Molecular Medicine Reports, 12, 2211-2216. https://doi.org/10.3892/mmr.2015.3562
MLA
Wang, Y., Wang, H., Song, T., Zou, Y., Jiang, J., Fang, L., Li, P."HOTAIR is a potential target for the treatment of cisplatin‑resistant ovarian cancer". Molecular Medicine Reports 12.2 (2015): 2211-2216.
Chicago
Wang, Y., Wang, H., Song, T., Zou, Y., Jiang, J., Fang, L., Li, P."HOTAIR is a potential target for the treatment of cisplatin‑resistant ovarian cancer". Molecular Medicine Reports 12, no. 2 (2015): 2211-2216. https://doi.org/10.3892/mmr.2015.3562